Direct compression tablet manufacture with Muli Powder as the active fraction begins with a preformulation assessment of particle size distribution, moisture content, and flow function coefficient because these parameters dictate whether the powder can be blended without granulation. The API lot is passed through a cone mill fitted with a 0.5 mm round screen at 1,500 rpm; oversize retained on a 250 µm sieve is recycled into the mill until D90 falls within 100–150 µm. Moisture content is controlled below 1.2% w/w by tray drying at 60°C with air velocity of 0.4 m/s when ambient relative humidity exceeds 60% RH. A 300 L bin blender rotating at 12 rpm for 15 minutes produces a homogeneous blend with acceptance value ≤ 15 under USP <905>. The direct compression formula consists of Muli Powder 10–30% w/w, microcrystalline cellulose PH-102 40–65% w/w, calcium hydrogen phosphate dihydrate 10–20% w/w, crospovidone 2–5% w/w, and magnesium stearate 0.25–1.0% w/w. Compression on a rotary tablet press using 8 mm round concave tooling at a main compression force of 12–18 kN yields tablets with hardness 60–90 N and friability below 1.0% per Ph. Eur. 2.9.7. Terminal products include scored tablets for companion animal dosing and immediate-release bolus tablets for ruminants. Lamination occurs when residual moisture exceeds 1.2% w/w or when magnesium stearate is blended beyond 5 minutes at full speed, so lubrication time is strictly limited after initial blending.

Stability batches for the tablet presentation are stored under VICH GL5 conditions at 25°C/60% RH and 40°C/75% RH for six months. Dissolution testing follows USP <711> Apparatus II with 900 mL of pH 6.8 phosphate buffer at 37±0.5°C and 50 rpm paddle speed. Batch records require tablet press turret speed below 60 rpm for scored tablets because higher speeds increase capping frequency on production-scale equipment.

What Limits Sterile Filtration of Muli Powder Injectable Solutions?

Aqueous solubility screening in Water for Injection at 20±2°C determines whether Muli Powder can be presented as a solution or must be formulated as a sterile suspension. If solubility remains below 10 mg/mL after 60 minutes of stirring at 500 rpm, a solution presentation is not technically feasible without a co-solvent; published solubility and pH-stability data for this specific configuration is limited. For a target injectable strength of 50 mg/mL, a screening vehicle of propylene glycol 20% v/v, ethanol 10% v/v, and Water for Injection 70% v/v is evaluated before progressing to aseptic filling. The compounded solution is passed through a 0.22 µm polyethersulfone membrane filter under nitrogen pressure of 1.0–1.5 bar; filter integrity is verified by bubble point before and after filtration. Terminal sterilization is applied at 121°C for 15 minutes, achieving an F0 of not less than 12 minutes, only if the API degradation profile remains within specification under stress conditions. Sterility testing follows USP <71>, bacterial endotoxin limits are set at 0.5 EU/mg for parenteral administration under USP <85>, and particulate matter is controlled per USP <788>. Terminal products include 10 mL single-dose ampoules, 50 mL single-dose vials, and 100 mL multidose vials, with all aseptic filling operations conducted in an ISO 14644-1:2015 Class 5 environment. A common production failure is non-sterile product caused by filter membrane incompatibility with co-solvent systems; polyvinylidene fluoride membranes are avoided when ethanol content exceeds 10% v/v because of wetting limitations.

When solubility data do not support a solution, Muli Powder is processed into a sterile suspension by wet milling with zirconium oxide beads to a particle size D90 below 20 µm, then dispersed in a vehicle containing sodium carboxymethylcellulose 0.5% w/v and polysorbate 80 at 0.1% w/v. The suspension is filled aseptically because terminal moist heat sterilization can accelerate crystal growth and caking. Syringeability is confirmed by measuring extrusion force through a 23G needle; values above 10 N indicate the need for further particle size reduction or viscosity adjustment. For lyophilized powder for injection, Muli Powder and mannitol 5% w/v are filled aseptically, frozen at -40°C, and lyophilized at a shelf temperature of -20°C under 0.1 mbar for 48 hours; residual moisture in the finished cake is held below 1.0% w/w.

For capsule filling operations, Muli Powder is rarely filled directly because volumetric dosator systems respond to bulk density fluctuations. The powder is first compacted in a roller compactor at 25 kN compaction force, then milled through a 1.0 mm screen to produce granules with bulk density 0.6–0.8 g/cm³ and D50 of 180–250 µm. Direct filling of uncompacted powder into size 3 hard gelatin capsules produces fill weight variability greater than 5% RSD when the angle of repose exceeds 40° per USP <1174> powder flow characterization. The fill blend contains Muli Powder 20–40% w/w, lactose monohydrate 45–65% w/w, pregelatinized starch 5–15% w/w, talc 1–3% w/w, and sodium stearyl fumarate 0.5–1.5% w/w. Capsule filling is performed on a dosator-type machine at 30,000 capsules/hour with in-line checkweighing every 15 minutes; fill weight limits are set at ±5% of target per Ph. Eur. 2.9.5. Dissolution testing is conducted using USP <711> Apparatus II with 900 mL of pH 6.8 phosphate buffer at 37±0.5°C and 50 rpm paddle speed. Terminal products include 250 mg and 500 mg veterinary capsules for oral administration in dogs, cats, and calves. Storage below 25°C and 60% RH prevents gelatin embrittlement and moisture migration from capsule shell to powder bed.

Premix Segregation Risks in Low-Inclusion Medicated Feed

Medicated premix manufacture with Muli Powder is a dilution process in which the active fraction must survive multiple transfer steps without segregation. A typical veterinary premix contains Muli Powder at 1–5% w/w, ground corn cob carrier at 94–98% w/w, and soybean oil dust suppressant at 0.5–1.0% w/w. The first dilution is a 1:10 trituration prepared in a ribbon mixer at 50 rpm for 10 minutes; the trituration is then added to the remaining carrier in a double-ribbon mixer using the sandwich loading sequence: half carrier, trituration, remaining carrier. Mixing continues for 15 minutes after the final addition, and homogeneity samples are collected from 10 locations with acceptance at coefficient of variation ≤ 5% in accordance with 21 CFR 225 current good manufacturing practice for medicated feeds. Terminal products include medicated premix bags for feed mills, mineral supplement packs for dairy cows, and starter feed premixes for pigs. A production-scale failure occurs when the premix is discharged through a pneumatic conveyor after mixing; free-fall discharge into totes is preferred because Muli Powder with bulk density below 0.5 g/cm³ can separate from denser carrier particles during pneumatic transfer. Final feed inclusion rates are calculated from the premix assay and the target dose per kg body weight, with a total mixed ration mixing time of 20 minutes in a horizontal paddle mixer to achieve homogeneity before pelleting. If Muli Powder is heat-labile, the finished feed is presented as meal or crumble rather than steam-conditioned pellets to avoid thermal degradation above 80°C.

When Fluid Bed Granulation Is Required for Muli Powder Oral Granules

For oral granule presentations, the decision to use wet granulation is driven by flow properties and dose uniformity requirements rather than by any intrinsic property of Muli Powder. If the angle of repose exceeds 45° and Carr index exceeds 35, fluid bed top-spray granulation is selected to convert the API into free-flowing granules. A Glatt GPCG-5 fluid bed is charged with Muli Powder 10–50% w/w, lactose monohydrate 40–80% w/w, and maize starch 5–10% w/w. The binder solution is povidone K-30 at 5% w/w in purified water, sprayed at 20 g/min with atomization air pressure 2.5 bar, inlet air temperature 60°C, and product temperature 35–40°C. Drying continues after binder application until loss on drying is below 2.0% w/w by Ph. Eur. 2.2.32. The dried granules are screened through a 850 µm sieve and packaged into sachets. Terminal products include oral granules for horses, swine, and poultry, usually reconstituted into feed or drinking water at the point of administration. Over-wetting is a batch failure mode when the spray rate exceeds the evaporation capacity of the fluid bed; this produces agglomerates larger than 1,000 µm that fail to disperse upon use. For moisture-sensitive APIs, dry granulation or roller compaction is substituted, but this requires a different binder-lubricant system.

Oral solution compounding from Muli Powder requires a fixed order of addition to avoid precipitation and undissolved particles reaching the packaging line. A 1,000 L stainless steel mixing vessel with a bottom-mounted high-shear mixer running at 1,500 rpm disperses the API into deionized water heated to 40±2°C. If the equilibrium solubility exceeds 20 mg/mL, a 5% w/v stock solution is prepared; if not, a suspending agent such as xanthan gum at 0.3–0.5% w/v is hydrated under vacuum before API addition. Final product pH is adjusted with 0.1 M citrate buffer to 5.5–6.5 after the API is fully dissolved or dispersed; adding buffer before complete dissolution causes localized nucleation and crystal growth. The finished liquid is passed through a 10 µm polypropylene bag filter and filled into 500 mL and 1 L HDPE bottles with tamper-evident caps. Terminal products include drinking water medications for poultry and swine, typically administered through proportioner medicators at 1–5% v/v stock solution dilution. Microbiological quality is evaluated per Ph. Eur. 5.1.4, and preservative efficacy is tested per Ph. Eur. 5.1.3 for multidose containers. A processing failure observed in production is gelling of xanthan gum when it is added directly to a high-shear zone without sufficient hydration; the gum must be prehydrated in a separate vessel at 30°C for 30 minutes before transfer.

When a dry powder presentation is selected for oral administration, blending is limited to formulations where the dose is sufficiently large to permit acceptable weight variation. A 50 kg V-blender rotating at 25 rpm for 20 minutes is used for batch sizes up to 50 kg; for larger batches, a 500 L tumbler blender with an intensifier bar at 3,000 rpm is substituted. The fill formula consists of Muli Powder 5–20% w/w, anhydrous lactose 70–90% w/w, citric acid 0.5–2% w/w for pH adjustment, and colloidal silicon dioxide 0.2–0.5% w/w to improve flow. The powder is filled into 100 g, 500 g, and 1 kg HDPE jars or foil-lined sachets. Terminal products include in-feed top-dress powders and oral administration powders for cattle, sheep, and swine. Loss on drying is maintained below 1.0% w/w because higher moisture activates citric acid and can cause caking during storage. A distinct production risk is over-blending in tumbler mixers, which charges cohesive API particles and leads to re-agglomeration; mixing time must be confirmed by powder blend uniformity sampling at 10 positions.